Repositorio de producción científica de la Universidad de Sevilla

Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain

Opened Access Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain

Citas

buscar en

Estadísticas
Icon
Exportar a
Autor: Salavert, Miguel
Pascual Hernández, Álvaro
Cobo, Javier
Aragón, Belén
Maratia, Stefano
Aceituno, Susana
Grau, Santiago
Departamento: Universidad de Sevilla. Departamento de Microbiología
Fecha: 2018
Publicado en: Advances in Therapy, 35 (11), 1920-1934.
Tipo de documento: Artículo
Resumen: Introduction Clostridium difficile infection (CDI) is the major cause of infectious nosocomial diarrhoea and is associated with considerable morbidity, mortality and economic impact. Bezlotoxumab administered in combination with standard of care (SoC) antibiotic therapy prevents recurrent CDI. This study assessed the cost-effectiveness of bezlotoxumab added to SoC, compared to SoC alone, to prevent the recurrence of CDI in high-risk patients from the Spanish National Health System perspective. Methods A Markov model was used to simulate the natural history of CDI over a lifetime horizon in five populations of patients at high risk of CDI recurrence according to MODIFY trials: (1) ≥ 65 years old; (2) severe CDI; (3) immunocompromised; (4) ≥ 1 CDI episode in the previous 6 months; and (5) ≥ 65 years old and with ≥ 1 CDI episode in the previous 6 months. The incremental cost-effectiveness ratio (ICER) expressed as cost per quality-adjusted life-year (QALY) gained was calculated. Det...
[Ver más]
Cita: Salavert, M., Pascual Hernández, Á., Cobo, J., Aragón, B., Maratia, S., Aceituno, S. y Grau, S. (2018). Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain. Advances in Therapy, 35 (11), 1920-1934.
Tamaño: 1.489Mb
Formato: PDF

URI: https://hdl.handle.net/11441/80741

DOI: 10.1007/s12325-018-0813-y

Ver versión del editor

Mostrar el registro completo del ítem


Esta obra está bajo una Licencia Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Internacional

Este registro aparece en las siguientes colecciones